CLAIMS

1. A pharmaceutical composition, wherein the pharmaceutical composition is a multiparticulate composition comprising a plurality of pellets, wherein each pellet comprises:

a core;

an API layer on the core, wherein the API layer comprises verinurad or a pharmaceutically acceptable salt thereof;

a rate-controlling polymer layer on the API layer; and

a sodium alginate layer on the release-rate controlling polymer layer.

2. The pharmaceutical composition of claim 1, wherein the rate-controlling polymer layer comprises ethyl cellulose.

3. The pharmaceutical composition of claim 1 or 2, wherein the rate-controlling polymer layer comprises polyvinylpyrrolidone.

4. The pharmaceutical composition of claim 1 or 2, wherein the rate-controlling polymer layer comprises hydroxypropyl cellulose.

5. The pharmaceutical composition of any one of the preceding claims, wherein the core comprises microcrystalline cellulose.

6. The pharmaceutical composition of any one of the preceding claims, wherein the API layer comprises verinurad.

7. The pharmaceutical composition of any one of the preceding claims, wherein the API layer further comprises hydroxypropyl methylcellulose.

8. The pharmaceutical composition of any one of the preceding claims, wherein the API layer further comprises a xanthine oxidase inhibitor.

9. The pharmaceutical composition of claim 8, wherein the xanthine oxidase inhibitor is allopurinol.

10. The pharmaceutical composition of any one claims 1 to 7, wherein the pharmaceutical composition further comprises a xanthine oxidase inhibitor.

11. The pharmaceutical composition of claim 10, wherein the xanthine oxidase inhibitor is allopurinol.

12. The pharmaceutical composition of any one of the preceding claims, wherein the sodium alginate has a glucuronic acid content between 65% and 75%, and a mannuronic acid content between 25% and 35%.

13. The pharmaceutical composition of any one of the preceding claims, wherein the amount of the sodium alginate layer is between 15 wt% and 25 wt%.

14. A pharmaceutical composition, wherein the pharmaceutical composition is a multiparticulate composition comprising a plurality of pellets, wherein each pellet comprises:

a core comprising microcrystalline cellulose;

an API layer on the core, wherein the API layer comprises verinurad or a pharmaceutically acceptable salt thereof;

a rate-controlling polymer layer on the API layer, wherein the rate-controlling polymer layer comprises ethyl cellulose and polyvinylpyrrolidone; and

a sodium alginate layer on the release-rate controlling polymer layer, wherein the sodium alginate has a glucuronic acid content between 65% and 75%, and a mannuronic acid content between 25% and 35%.

15. The pharmaceutical composition of claim 14, wherein the amount of the sodium alginate layer is between 15 wt% and 25 wt%.

16. The pharmaceutical composition of claim 14 or 15, wherein the API layer comprises verinurad.

17. The pharmaceutical composition of any one of claims 14 to 16, wherein the API layer further comprises a xanthine oxidase inhibitor.

18. The pharmaceutical composition of claim 17, wherein the xanthine oxidase inhibitor is allopurinol.

19. The pharmaceutical composition of any one of claims 14 to 16, wherein the pharmaceutical composition further comprises a xanthine oxidase inhibitor.

20. The pharmaceutical composition of claim 19, wherein the xanthine oxidase inhibitor is allopurinol.

21. Use of the pharmaceutical composition of any one of the preceding claims in the manufacture of a medicament for reducing serum uric acid levels in a human, wherein the pharmaceutical composition is to be administered to the human.

22. Use of the pharmaceutical composition of any one of claims 1-20 in the manufacture of a medicament for treating or preventing hyperuricemia, gout, gouty arthritis, recurrent gout attacks, polycythemia, myeloid metaplasia, inflammatory arthritis, nephrolithiasis (kidney stones), joint inflammation, urolithiasis (formation of calculus in the urinary tract), deposition of urate crystals in joints, deposition of urate crystals in renal parenchyma, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, gout flare, tophaceous gout, chronic kidney disease, kidney failure, heart failure, hypertension, cardiovascular disease, coronary heart disease, or a combination thereof in a human, wherein the pharmaceutical composition is to be administered to the human.

23. Use of the pharmaceutical composition of any one of claims 1-20 in the manufacture of a medicament for treating or preventing chronic kidney disease in a human, wherein the pharmaceutical composition is to be administered to the human.

24. Use of the pharmaceutical composition of any one of claims 1-20 in the manufacture of a medicament for treating or preventing heart failure in a human, wherein the pharmaceutical composition is to be administered to the human.

25. The pharmaceutical composition of any one of claims 1-20 for use in therapy.